SOFIE Biosciences Announces First Patient Dosed in [18F]FAPI-74 Phase 3 Study First dose at RadNet, in partnership with Helios Clinical and The Oncology Institute of Hope and Innovation, in …

With our premier radiopharmacy network, mature contract manufacturing services and high value theranostic intellectual property, SOFIE is dedicated to improving patient health.

SOFIE has built a high-capacity PET radiopharmaceutical network capable of delivering large volumes of products to as many patients as possible. Our product lines include FDG, Pylarify, Neuraceq, and …

Our team works alongside our Pharma and Academic partners to revolutionize clinical diagnostics and therapeutics to better understand and treat the biology of disease.

Transparency in Coverage (TiC) regulations requires health insurers and group Health Plans to post their provider link on company websites. View SOFIE’s Link here View our Privacy Policy

SOFIE is dedicated to providing reliable, high quality radiopharmaceuticals and cutting-edge technologies

In Nov 2019, SOFIE Biosciences (SOFIE) licensed quinoline-based PET tracers, developed by the team at Heidelberg University, that act as FAP inhibitors (FAPI) and showed promising clinical data in a …

GE HealthCare and SOFIE Biosciences (SOFIE) announced a partnership to develop, manufacture and commercialize SOFIE’s Gallium-68 and Fluorine-18 labelled diagnostics targeting fibroblast …

We provide our clients with highest quality radiopharmaceuticals, reliably delivered with care to imaging centers from coast-to-coast.

Jun 9, 2025 · SOFIE is continuing to accept applications for our FAPI Outreach Program. This program aims to raise awareness and foster collaboration in the field of molecular imaging, specifically …